JOSH BILENKER

Josh Bilenker stands as a prominent figure in the life sciences venture capital landscape, serving as a Partner at Aisling Capital. At Aisling, he plays a pivotal role in identifying, evaluating, and investing in groundbreaking biotechnology and pharmaceutical companies, with a particular emphasis on oncology and novel drug development platforms. His unique blend of scientific acumen, clinical experience, and entrepreneurial leadership makes him an invaluable asset to the firm and its portfolio companies.

Bilenker's investment focus at Aisling Capital is deeply rooted in his extensive career dedicated to advancing medical innovation. He seeks out companies that are developing transformative therapies, often with a strong scientific foundation and the potential to address significant unmet medical needs. His expertise spans early-stage drug discovery through clinical development and regulatory approval, allowing him to provide strategic guidance that extends far beyond capital investment. He is known for his hands-on approach, frequently taking active roles in the companies he supports, including co-founding and serving as CEO.

Prior to joining Aisling Capital, Dr. Bilenker built an impressive career marked by significant achievements. Most notably, he was the co-founder and Chief Executive Officer of Loxo Oncology, a biotechnology company focused on developing highly selective medicines for patients with genetically defined cancers. Under his leadership, Loxo Oncology achieved remarkable success, culminating in its acquisition by Eli Lilly for approximately $8 billion, a testament to its innovative pipeline and clinical breakthroughs. This experience provided him with unparalleled insights into building and scaling successful biotech ventures from inception to exit.

Before his entrepreneurial endeavors, Bilenker held key positions that shaped his understanding of drug development and regulation. He served in the Office of Oncology Drug Products at the U.S. Food and Drug Administration (FDA), where he gained critical experience in the regulatory pathways for cancer therapies. His background also includes time at Merck Research Laboratories, further solidifying his foundation in pharmaceutical research and development. Academically, he holds an M.D. from Johns Hopkins University School of Medicine and a Ph.D. from The Rockefeller University, underscoring his deep scientific credentials.

Beyond Loxo Oncology, Josh Bilenker has been instrumental in the creation and leadership of several other innovative companies. He co-founded and served as CEO of Kyn Therapeutics, Neogene Therapeutics, and Scorpion Therapeutics, all of which are focused on cutting-edge approaches to cancer treatment and other serious diseases. These roles highlight his consistent strategy of identifying promising scientific concepts and actively building companies around them, driving them towards clinical success and significant impact for patients. His strategic vision and operational expertise continue to make him a driving force in the life sciences investment community.